HitGen(SH:688222) Shang Hai Zheng Quan Bao·2025-11-14 20:07Group 1 - The core point of the announcement is the resolution of the second extraordinary general meeting of shareholders held by Chengdu XianDao Pharmaceutical Development Co., Ltd. on November 14, 2025, which included the approval of a proposal to apply for the registration and issuance of non-financial corporate debt financing instruments in the interbank bond market [1][2][3]. - The meeting was conducted in compliance with the Company Law and the company's articles of association, utilizing a combination of on-site and online voting methods [2][3]. - All nine directors attended the meeting, along with the board secretary and the financial officer, ensuring a quorum for decision-making [4][5]. Group 2 - The proposal regarding the issuance of non-financial corporate debt financing tools was passed with more than half of the valid voting rights held by attending shareholders [3]. - The legal proceedings of the meeting were witnessed by Beijing Junhe (Chengdu) Law Firm, confirming that the meeting's procedures and resolutions were lawful and valid [4][5].